Abstract
Simple SummaryThis review discusses the prominent highlights of SH003, a herbal mixture that has the potential to become a notable anticancer agent in the future. Although developing an anticancer drug may take a lengthy approval process for any natural compounds or herbal mixtures to validate the positive effects from both non-clinical and clinical studies, the previous studies of SH003 have so far shown positive results in various malignancies, from both non-clinical and clinical studies.Cancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound interest as chemopreventive agents for reducing burden for patients. SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, showed the potential to act as an anticancer agent in previous research studies. A narrative review was conducted to present the significant highlights of the total 15 SH003 studies from the past nine years. SH003 has shown positive results in both in vivo and vitro studies against various types of cancer cells; furthermore, the first clinical trial was performed to identify the maximum tolerated dose among solid cancer patients. So far, the potential of SH003 as a chemotherapeutic agent has been well-documented in research studies; continuous work on SH003’s efficacy and safety is required to facilitate better cancer patient care but is part of the knowledge needed to understand whether SH003 has the potential to become a pharmaceutical.
Highlights
Cancer is the leading cause of death worldwide, according to the World HealthOrganization [1]
SH003 is a mixture of Huang-Qi (Astragalus membranaceus; AG), Dang-Gui (Angelica gigas; AM), and Gua-Lou-Gen (Trichosanthes Kirilowii; TK), which are traditionally used in East Asian medicine
The results of an MTT cell viability assay showed that the co-treatment of SH003 and docetaxel synergistically inhibited the viability of non-small cell lung cancer (NSCLC) A549 and H460 cell lines
Summary
The rise of natural compounds as anticancer agents and its relation to cancer treatment has been discussed among patients since conventional chemotherapy has posed a considerable burden for cancer patients. Herbal medicines have been used with conventional chemotherapy or radiotherapy as a combination therapy to improve the efficacy of cancer treatment and reduce side effects, along with possible complications. Natural compounds and herbal medicines, as well as herbal mixtures, have shown a considerable number of positive effects and have offered a superb opportunity for discovering therapeutic agents for the treatment of cancer. The study aims to highlight the potentials of SH003, a herbal mixture, working as a vital anticancer agent, while providing evidence that it targets multiple metabolic pathways in both single-dose therapy and combined therapy along with conventional chemotherapeutics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
